NCT01196728: Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes |
|
|
| Completed | 1 | 16 | Europe | CM3.1-AC100 | CellMed AG, a subsidiary of BTG plc. | Type II Diabetes Mellitus | 11/10 | 11/10 | | |
